Article

eyeforpharma goes VIRTUAL

In light of the rapidly evolving impact of the COVID-19 virus, eyeforpharma has decided to turn eyeforpharma Barcelona and eyeforpharma Philadelphia into completely virtual events.

Evolving HTA frameworks to accelerate innovation

Iterative evidence generation and demonstrating value over time could help unlock delays in getting cures out, saving more lives, says Janss...

Can we afford to pay for future cures?

Medical innovation is racing ahead of healthcare’s ability to innovate on payments, but new ideas are emerging

Into pharma's roaring twenties

A new decade is here. And despite the incredible science, pharma is ill-equipped.

Advancing RWE together with academia

Pharma can realise the potential of RWE faster by collaborating more effectively with academia but first it must build trust

Access and Evidence

Latest Articles

Evolving HTA frameworks to accelerate innovation

Andrew Stone, (Mar 14, 2020)

Iterative evidence generation and demonstrating value over time could help unlock delays in getting cures out, saving more lives, says Janssen’s Clare Hague
Can we afford to pay for future cures?

Ulrich Neumann, (Jan 24, 2020)

Medical innovation is racing ahead of healthcare’s ability to innovate on payments, but new ideas are emerging
Into pharma's roaring twenties

Paul Simms, (Jan 14, 2020)

A new decade is here. And despite the incredible science, pharma is ill-equipped.
Advancing RWE together with academia

Katie Osborne, (Jan 2, 2020)

Pharma can realise the potential of RWE faster by collaborating more effectively with academia but first it must build trust
Prescription drug pricing: The times they are a changin’

Ulrich Neumann, (Nov 25, 2019)

The political mood in the US on drug pricing at a national and state level is putting the pressure on pharma to demonstrate value
Putting a price on life: Is the answer outside pharma?

Nicola Davies, (Nov 4, 2019)

Gene replacement and cell-based therapies are here to cure, but are we ready for them? The current difficulty pricing groundbreaking healthcare advancements suggests maybe not.
Putting The I in Pills

Izzy Gladstone, (Jun 27, 2019)

Individualised medicine has so far failed to live up to the hype but innovations in the field are on the cusp of disrupting the way pharma and healthcare develop and provide treatments.
Embracing Early Access

Katie Osborne, (Jan 22, 2019)

Compassionate use programs offer hope to patients who have ran out of options. But the benefits must be weighed against the risks.
RWE: The Missing Link

Nicola Davies, (Jan 7, 2019)

Linking real-world datasets is essential to deliver true insights
Gold Standard: Standardizing RWD

Nicola Davies, (Jan 4, 2019)

If real-world data is to deliver on its promise, it needs to be standardized